English 
Español 
français 
العربية Search
Search
Baricitinib (brand name Olumiant) is a prescription medication known as a JAK inhibitor. It works by blocking enzymes that cause inflammation in the body.
It is primarily used to treat autoimmune conditions like rheumatoid arthritis and severe alopecia areata. It was also authorized to treat certain hospitalized COVID-19 patients.
Important warnings include an increased risk of serious infections, blood clots, cancer, and heart-related events. It requires close medical supervision due to these potential side effects.
Items | Specification |
| Appearance | White or off-white crystalline powder |
| Assay | ≥99% |
| Molecular Formula | C16H17N7O2S |
| Molecular Weight | 371.41688 |
| Product parameters | |
| Cas number: | 1187594-09-7 |
| Appearance: | White or off-white crystalline powder |
| Purity: | 99%min |
| MOQ: | 10g |
| Price: | Negotiable |
| Package details: | 10g,100g,1kg/foil bag;25kg/drum |
| Brand: | Fortunachem |
Baricitinib is a prescription medication belonging to a class of drugs known as Janus kinase (JAK) inhibitors. It works by modulating the immune system to reduce inflammation and is used to treat several autoimmune and inflammatory conditions.
Its most common brand name is Olumiant.
To understand how it works, it's helpful to know about the JAK-STAT pathway:
The Pathway: This is a crucial communication system inside cells, particularly immune cells. When inflammatory cytokines (messenger proteins) bind to a cell, they activate enzymes called Janus kinases (JAKs).
The Signal: The JAKs then send a signal (via proteins called STATs) to the nucleus of the cell, instructing it to create more inflammatory agents. This process is like turning up the volume on inflammation.
Baricitinib's Action: Baricitinib acts as an inhibitor. It blocks the activity of specific JAK enzymes (primarily JAK1 and JAK2). By doing this, it interrupts the inflammatory signaling pathway, effectively "turning down the volume" on the immune response and reducing inflammation and its symptoms.
Baricitinib is approved by regulatory agencies like the FDA and EMA for several conditions:
Rheumatoid Arthritis (RA): It is used to treat moderate-to-severe active RA in adults who have not responded adequately to one or more tumor necrosis factor (TNF) antagonist drugs. It can be used alone or in combination with other drugs like methotrexate.
Alopecia Areata (AA): It is approved for the treatment of severe alopecia areata, an autoimmune disease that causes patchy or total hair loss (including on the scalp and body). It was the first JAK inhibitor approved for this condition.
COVID-19: During the pandemic, it received emergency or temporary authorization for use in combination with other drugs (like corticosteroids) to treat hospitalized adults with COVID-19 who require supplemental oxygen, a ventilator, or a life-support machine. It helps by reducing the dangerous, excessive inflammation ("cytokine storm") caused by the virus.
It is an oral tablet, taken once daily with or without food.
The dosage (2 mg, 4 mg, or others) depends entirely on the condition being treated and the patient's individual health profile. It is crucial to follow the dosage prescribed by a doctor.
Like all powerful medications, baricitinib carries risks and requires careful medical supervision.
Serious Side Effects (require immediate medical attention):
Infections: Significantly increases the risk of serious and sometimes fatal infections (e.g., tuberculosis, herpes zoster (shingles), bacterial, viral, fungal, and other opportunistic infections).
Cancer: JAK inhibitors may increase the risk of certain cancers, including lymphoma and skin cancers.
Blood Clots: Increased risk of blood clots in the veins (deep vein thrombosis - DVT, pulmonary embolism - PE), which can be life-threatening.
Cardiovascular Events: Increased risk of major adverse cardiovascular events (MACE), such as heart attack and stroke, especially in patients with existing cardiovascular risk factors.
Laboratory Changes: Can cause changes in lab results, including low blood cell counts (neutropenia, anemia), increases in LDL cholesterol ("bad" cholesterol), and increases in liver enzymes.
Common Side Effects:
Upper respiratory tract infections (like the common cold)
Headache
Nausea
Herpes simplex and zoster (cold sores and shingles)
Medical History: Your doctor will thoroughly review your history, especially regarding:
Current or past infections (TB, hepatitis, shingles)
Cancer
Blood clots
Heart problems, stroke, or blood vessel issues
Liver or kidney problems
Vaccinations: All vaccinations should be brought up to date before starting treatment. Live vaccines are not recommended while taking baricitinib.
Pregnancy and Breastfeeding: The risks are not fully known. Discuss with your doctor if you are pregnant, planning to become pregnant, or breastfeeding.
Monitoring: Regular blood tests and health check-ups are essential to monitor for the serious side effects listed above.
| Aspect | Description |
|---|---|
| Drug Class | Janus Kinase (JAK) Inhibitor |
| Brand Name | Olumiant |
| Primary Use | Treats autoimmune inflammation in Rheumatoid Arthritis and Alopecia Areata. Also used for severe COVID-19. |
| Key Mechanism | Blocks JAK enzymes to interrupt the inflammatory signaling pathway in immune cells. |
| Important Risks | Serious infections, blood clots, cancer, major cardiovascular events. Requires ongoing medical monitoring. |
Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice. Always talk to your doctor or a qualified healthcare provider about any questions you may have regarding a medical condition or treatment.
Guaranteed purity
High quality & competitive price
Quality control
Fast feedback
Prompt shipment
Fortunachem Provides Not Only Professional Chemical Products But Also Professional Help
Keeping you up-to-date with all the latest information, news, and events about Fortunachem!
Quick Links
Add:
E-mail:
